Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Alternative Names: Lymphoaim; Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Tc99m tilmanocept; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; National Cancer Institute (USA); National Institute of Health Clinical Center; Navidea Biopharmaceuticals; Norgine; University of California, San Diego
  • Class Heavy metals; Imaging agents; Radiopharmaceutical diagnostics; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase III Cardiovascular disorders; Rheumatoid arthritis
  • Phase II Cervical cancer; Kaposi's sarcoma
  • Clinical Phase Unknown Mouth neoplasm
  • No development reported Colorectal cancer; Crohn's disease; Endometrial cancer; Liver metastases; Non-alcoholic steatohepatitis

Most Recent Events

  • 25 Jul 2024 Navidea Biopharmaceuticals terminates a phase IIb trial in Rheumatoid arthritis (Diagnosis, In adults, In the elderly) in USA and the United Kingdom due to sponsor decision (Intradermal, Injection) (NCT04078191)
  • 25 Jul 2024 Navidea Biopharmaceuticals terminates a phase III trial in Rheumatoid arthritis (Diagnosis, In adults, In the elderly) in USA due to sponsor decision (IV) (NCT05246280)
  • 14 Jun 2023 Navidea Biopharmaceuticals entered into an amendment with Cardinal Health

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top